期刊文献+

健康志愿者氯沙坦钾片的生物等效性研究 被引量:5

Studies on Bioequivalence of Losartan Potassium Tablet in Healthy Volunteers
暂未订购
导出
摘要 目的建立人血浆中氯沙坦及其代谢物氯沙坦羧酸(EXP3174)浓度的测定方法,并评价2种氯沙坦钾片在健康志愿者体内的生物等效性。方法 23例男性健康志愿者随机双周期交叉给药,口服受试制剂和参比制剂50mg,清洗期1周,HPLC-MS/MS法测定血浆中氯沙坦和HPLC-荧光法测定血浆中氯沙坦代谢物EXP3174浓度。所得数据经WinNonlin 6.0软件分析,计算氯沙坦及EXP3174在人体内的药代动力学参数。结果口服受试制剂和参比制剂后,志愿者的氯沙坦和EXP3174主要药代动力学参数如下:氯沙坦Cmax分别为(244.8561±86.9741)ng/mL,(266.8621±115.5986)ng/mL;AUC0-t分别为(451.4±151.8)ng/(h mL)(,459.4±163.7)ng/(h mL);AUC0-∞分别为(469.8±155.1)ng/(h mL)(,477.9±166.2)ng/(h mL);t1/2分别为(1.55±0.32)h,(1.65±0.37)h;Tmax分别为:(1.09±0.62)h,(1.25±0.75)h。EXP3174 Cmax分别为(399.4±100.5)ng/mL,(426.8±132.6)ng/mL;AUC0-t分别为(3231±1064)ng/(h mL),(3152±1058)ng/(h mL);AUC0-∞分别为(3458±1152)ng/(h mL),(3408±1061)ng/(h mL);t1/2分别为(6.86±2.25)h,(5.77±1.47)h;Tmax分别为:(3.48±0.89)h,(3.13±0.69)h。结论氯沙坦钾受试制剂与参比制剂在人体内具有生物等效性。 Objective To establish a method for determination of losartan and its metabolite EXP3174 in human plasma.To evaluate the bioequivalence of 2 kinds of losartan potassium tablets in healthy volunteers.Methods A single oral dose of 50 mg test or reference preparation was adminidtrated to 23 healthy male volunteers in a randomized cross-over study with 1 week washout interval.The plasma concentrations of losartan and EXP3174 were determined by HPLC-MS/MS and HPLC-FLU.The pharmacokinetic parameters were calculated and statistically analyzed by WinNonlin 6.0 software.Results The pharmacokinetic parameters of losartan and EXP-3174 of test and reference preparation were as fllows: For losartan,Cmax were(244.8561±86.9741) ng/mL,(266.8621 ±115.5986) ng/mL;AUC0-twere(451.4±151.8) ng/(h mL),(459.4±163.7) ng/(h mL);AUC0-∞were(469.8±155.1) ng/(h mL),(477.9±166.2)ng/(h mL);t1/2were(1.55 ±0.32) h,(1.65±0.37) h;Tmax were(1.09±0.62) h,(1.25±0.75) h.For EXP3174,Cmax were(399.4±100.5) ng/mL,(426.8±132.6) ng/mL;AUC0-t were(3231± 1064) ng/(h mL),(3152±1058) ng/(h mL);AUC0-∞ were(3458±1152) ng/(h mL),(3408±1061) ng/(h mL);t1/2 were(6.86±2.25)h,(5.77±1.47) h;Tmax were(3.48±0.89) h,(3.13±0.69) h.Conclusion Test and reference drugs of losartan potassium are bioequivalent.
作者 金杰
出处 《中国医药指南》 2013年第2期3-5,共3页 Guide of China Medicine
关键词 氯沙坦 EXP3174 高效液相色谱-串联质谱 高效液相色谱-荧光检测 生物等效性 Losartan EXP3174 HPLC-MS/MS HPLC-FLU Bioequivalence
  • 相关文献

参考文献11

二级参考文献42

  • 1赵宏宇,郑强,刘洋,李铁刚.氯沙坦钾治疗肾实质性高血压和尿蛋白的疗效观察[J].实用药物与临床,2005,8(3):34-35. 被引量:9
  • 2张金彦,沈芊.血管紧张素Ⅱ受体拮抗药的临床应用与不良反应[J].中国药房,2007,18(23):1826-1828. 被引量:2
  • 3[10]NAKASHIMA M, UMEMURA K. The clinical pharmacology of losartan in Japanese subjects and patients[J]. Blood Press Suppl,1996,2:62-66.
  • 4[11]SONG JC, WHITE CM. Pharmacologic, pharmacokinetic, and therapeutics differences among angiotensin Ⅱreceptor antagonists [J]. Pharmacotherapy, 2000,20(2):130-139.
  • 5[12]NEUTEL JM, KLEIN C, MEINICKE TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications[J].Blood Press,2002,11(5):302-309.
  • 6[13]PRASAD PP, YEH CM, GURRIERI P, et al. Pharmacokinetics of multiple doses of valsartan in patients with heart failure[J]. J Cardiovasc Pharmacol,2002,40(5):801-807.
  • 7[14]SMITH DH, MATZEK KM, KEMPTHORNE-RAWSOWL J. Dose response and safety of telmisartan in patients with mild to moderate hypertension[J]. J Clin Pharmacol,2000,40(12 Pt 1):1380-1390.
  • 8[15]SASAKI M, FUJIMURA A, HARADA K, et al. Clinical pharmacology of multiple-dose losartan an angiotensin Ⅱ receptor antagonist, in patients with essential hypertension[J]. J Clin Pharmacol, 1996, 36(5):403-408.
  • 9[16]RUILOPE L. Human pharmacokinetic/pharmacodynemic profile of irbesartan: a new potent angiotensin Ⅱ receptor antagonist[J]. J Hypertens Suppl,1997 ,15 (7):S15-S20.
  • 10[17]McCLELLAN KJ, GOA KL. Candesartan cilexetil. A review of its use in essential hypertension[J]. Drugs,1998,56(5):847-869.

共引文献48

同被引文献37

引证文献5

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部